Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Maharashtra witnessed a significant rise in chikungunya cases this year, with 5,757 infections. Patients are experiencing prolonged after-effects like joint pain, fatigue, and neurological ...

today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single ...

Pune reported nine suspected new cases of Guillain-Barre Syndrome (GBS), raising the city's total to 110 cases. Health officials have noted gender distribution, ventilator usage, and are conducting ...

The health officials said that a new Guillain-Barre Syndrome case was reported in Pune on Tuesday; number of suspected GBS ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ®, which showed a sustained 98.3% sero-response rate one-year after single ...

Tingling, weakness of hand-grip or foot drop could signal Guillain-Barré Syndrome (GBS), said <a target=_blank href=http ...

Pune is battling a growing health crisis as Guillain-Barre Syndrome (GBS), a rare immunological nerve disorder, has gripped ...